[Amikacin in urinary tract infections with so-called problem pathogens].
Amikacin (Biklin) was applied in 33 patients with and without renal insufficiency, suffering of non-obstructive inflammations of the urinary tract, caused by multiple resistant hospital germs. The dosage was 125.0--1000.0 mg/die, injected as short infusion and solved in dextrose 5%. The serum and urine concentrations were measured simultaneously. In 18 cases an infection could not be seen after a control period of 8 days up to 4 weeks. Persistence of bacteria happened in five cases. Reinfection could be noted in 5 other cases. Side effects--as oto- or nephrotoxicity, pathological changes of the differential blood count, increasing of the serum transaminases and phosphatases--were seen neither during nor after the therapy.
D000583:Amikacin / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004927:Escherichia coli Infections / Q000188:drug therapy; D006801:Humans; D007612:Kanamycin / Q000031:analogs & derivatives*; D011512:Proteus Infections / Q000188:drug therapy; D011552:Pseudomonas Infections / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000097:blood / Q000188:drug therapy*
D007612:Kanamycin; D000583:Amikacin
Amikacin bei Harnwegsinfektionen mit sog. Problemkeimen